Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 61186372NSC2007 | Other Identifier | Janssen Research & Development, LLC | |
| 2023-505863-35-00 | Registry Identifier | EUCT number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A: Enhanced Dermatologic Management | Experimental | Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical solution, and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab intravenously (Dose 1 for body weight [BW] less than 80 kilograms [kg] and Dose 2 for BW greater than or equal to [>=] 80 kg as IV infusion [Arm A]) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1). |
|
| Arm B: Standard-of-Care Dermatologic Management | Active Comparator | Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as IV infusion plus lazertinib, dose and dosing schedule as same as experimental arm. |
|
| Sub-study: Cohort A: Ruxolitinib | Experimental | Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to [>=] 2, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0) will be enrolled and receive reactive treatment with ruxolitinib in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amivantamab IV | Drug | Amivantamab will be administered. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment | Number of participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 weeks after initiation of anticancer treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With DAEIs by Severity Based on NCI-CTCAE v 5.0 | Number of participants with DAEIs by severity based on NCI-CTCAE v 5.0 will be reported. | Up to 12 weeks after initiation of anticancer treatment |
| Number of Participants With Grade >=2 DAEIs Within 6 Months After Initiation of Anticancer Treatment Based on NCI-CTCAE v 5.0 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving Best Response for the Dermatologic Adverse Event | Participants achieving best response within 12 weeks of treatment defined as NCI-CTCAE level of the dermatologic adverse event improvement by at least 1 level will be reported. | Up to 12 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ironwood Cancer and Research Center | Chandler | Arizona | 85224 | United States | ||
| City of Hope |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40923969 | Derived | Cho BC, Li W, Spira AI, Sauder M, Feldman J, Bozorgmehr F, Mak M, Smith J, Voon PJ, Liu B, Tian P, Tan JL, Yang CT, Shih JY, Karadurmus N, Cundom JE, Bertollo G, Cicin I, Nieva J, Ortega-Granados AL, Tomasini P, Nguyen D, Felip E, Schuchard J, Murphy SP, Anderson BG, Romero T, Xia Y, Sheng S, Bauml JM, Mahadevia PJ, Kam J, Nematian-Samani M, Simoes J, Wildgust M, Girard N. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. J Thorac Oncol. 2025 Oct;20(10):1517-1530. doi: 10.1016/j.jtho.2025.07.117. Epub 2025 Sep 9. |
Not provided
Not provided
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Sub-study: Cohort B: Tacrolimus | Experimental | Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade >= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treatment with tacrolimus in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib. |
|
| Amivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule | Experimental | Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per standard schedule. If a participant develops a dermatologic adverse event of interest (DAEI) they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1. |
|
| Amivantamab SC Expansion Cohort: Modified Schedule | Experimental | Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per modified schedule. If a participant develops a DAEI they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1. |
|
|
| Amivantamab SC | Drug | Amivantamab will be administered as SC injection. |
|
|
| Lazertinib | Drug | Lazertinib tablet will be administered orally. |
|
|
| Doxycycline | Drug | Doxycycline tablet will be administered orally. |
|
| Minocycline | Drug | Minocycline capsule will be administered orally. |
|
| Clindamycin | Drug | Clindamycin lotion will be used as topical application on the scalp. |
|
| Chlorhexidine | Drug | Chlorhexidine solution will be used as topical application on hands and feet. |
|
| Noncomedogenic skin moisturizer | Other | Noncomedogenic skin moisturizer will be used as topical application. |
|
| Ruxolitinib | Other | Ruxolitinib will be used to the affected skin area. |
|
| Tacrolimus | Other | Tacrolimus will be used as topical application to the affected skin area. |
|
| Zinc gluconate | Drug | Zinc gluconate tablet will be administered. |
|
| Propranolol | Drug | Propranolol tablet will be administered. |
|
| Timolol | Drug | Timolol will be used to the affected skin area. |
|
| Clobetasol | Drug | Clobetasol shampoo will be used on the scalp. |
|
Number of participants with Grade >=2 DAEIs within 6 months after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. |
| Up to 6 months after initiation of anticancer treatment |
| Number of Grade >= 2 DAEI Per Participants | Number of grade >= 2 DAEI per participants will be reported. | Up to 12 months |
| Time to First Occurrence of Grade >=2 DAEI | Time to first occurrence of Grade >=2 DAEI will be reported. | Up to 12 months |
| Time to Resolution of Grade >= 2 DAEI | Time to resolution of Grade >= 2 DAEI will be reported. | Up to 12 months |
| Number of Participants With Paronychia by Severity Based on NCI-CTCAE v 5.0 | Number of participants with paronychia by severity based on NCI-CTCAE v 5.0 will be reported. | Up to 6 months after initiation of anticancer treatment |
| Number of Participants With Scalp Rash by Severity Based on NCI-CTCAE v 5.0 | Number of participants with scalp rash by severity based on NCI-CTCAE v 5.0 will be reported. | Up to 12 months after initiation of anticancer treatment |
| Change From Baseline in Skindex Symptoms Domain Score up to 12 Months | Change from baseline in skindex symptoms domain score up to 12 months will be reported. The score of quality of life will be assessed using the Skindex-16 questionnaire. Skindex-16 is used for participants to rate skin conditions. | Baseline, up to Month 12 |
| Change From Baseline in Patient's Global Impression-Severity (PGI-S) Rash up to 12 Months | Change from baseline in PGI-S rash up to 12 months will be reported. Participant quality of life will be evaluated using PGI-S Rash. PGI-S is a single-item questionnaire assessing participants disease severity on a 7-point response scale. | Baseline, up to Month 12 |
| Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score up to 12 Months | Change from baseline in EORTC-QLQ-C30 score up to 12 months will be reported. EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. | Baseline, up to Month 12 |
| Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Patient-reported Outcome (PRO) up to 12 Months (for Amivantamab Subcutaneous Expansion Cohort Only) | The EQ-5D questionnaire is a brief, generic HRQOL assessment that can that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. EQ-5D scores include EQ-5D valuation index score (a weighted scoring of the 5 dimension scores with a possible range from 0 to 1), EQ-5D visual analog scale (VAS) is a vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health), and EQ5D descriptive system scores (five scores reflecting each of the 5 EQ-5D health dimensions ranging from 0 [no limitation] to 4 [incapacity]). | Baseline, up to Month 12 |
| Percentage of Participants With Dose Reductions, Dose Interruptions, and Dose Discontinuations of Anticancer Treatment due to DAEIs | Percentage of participants with dose reductions, dose interruptions, and dose discontinuations of anticancer treatment due to DAEIs will be reported. | Up to 12 months |
| Relative Dose Intensity (RDI) of Anticancer Treatment | Relative dose intensity of anticancer treatment will be reported. The relative dose intensity is defined as the ratio of total actually received dose versus total prescribed dose. | Up to 12 months |
| Percentage of Participants With Venous Thromboembolism (VTE) Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0 | Percentage of participants with VTE AEs (pulmonary embolism and deep vein thrombosis) by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. | Up to 12 months |
| Percentage of Participants With Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0 | Percentage of participants with AEs by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. | Up to 12 months |
| Progression Free Survival (PFS) | PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first. | Up to 12 months |
| Overall Response Rate (ORR) | ORR is defined as the percentage of participants who achieve a partial response (PR) or better response using RECIST v1.1 as assessed by the investigator. | Up to 12 months |
| Duration of Response (DoR) | DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST v1.1 response criteria. | Up to 12 months |
| Amivantamab SC Expansion Cohorts: Number of Participants With Grade >= 2 DAEIs Within 12 Weeks After Initiation of Anticancer Treatment | Participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 weeks after initiation of anticancer treatment |
| Amivantamab SC Expansion Cohorts: Percentage of Participants With an Improvement in DAEI After Starting Early Intervention | Percentage of participants showing an improvement in DAEI by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 months |
| Amivantamab SC Expansion Cohorts: Time to Improvement of DAEIs After Starting Early Intervention | Time to improvement of DAEIs by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 months |
| Duarte |
| California |
| 91010 |
| United States |
| Providence Fullerton | Fullerton | California | 92835 | United States |
| Los Angeles Cancer Network | Glendale | California | 91204 | United States |
| City of Hope Seacliff | Huntington Beach | California | 92648 | United States |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine | California | 92618 | United States |
| City of Hope Long Beach Elm | Long Beach | California | 90813 | United States |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | United States |
| Keck Hospital of USC | Los Angeles | California | 90033 | United States |
| USC Norris Oncology Hematology Newport Beach | Newport Beach | California | 92663 | United States |
| Kaiser Permanente Oakland Medical Center | Oakland | California | 94611 | United States |
| Kaiser Permanente Roseville Medical Center | Roseville | California | 95661 | United States |
| Kaiser Permanente San Francisco Medical Center | San Francisco | California | 94115 | United States |
| Kaiser Permanente Santa Clara Medical Center | Santa Clara | California | 95051 | United States |
| City of Hope South Pasadena | South Pasadena | California | 91030 | United States |
| Kaiser Permanente Northern California | Vallejo | California | 94589 | United States |
| Kaiser Permanente Walnut Creek Medical Center | Walnut Creek | California | 94596 | United States |
| University Cancer & Blood Center | Athens | Georgia | 30607 | United States |
| Hope and Healing Care | Hinsdale | Illinois | 60521 | United States |
| Oncology Hematology Associates | Springfield | Missouri | 65807 | United States |
| Renown Health Medical Oncology | Reno | Nevada | 89502 | United States |
| Hunterdon Hematology Oncology | Flemington | New Jersey | 08822 | United States |
| Clinical Research Alliance Inc | Westbury | New York | 11590 | United States |
| Regional Medical Oncology Center | Wilson | North Carolina | 27893 | United States |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | United States |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | United States |
| Valley Medical Center | Renton | Washington | 98055 | United States |
| Gundersen Health System | West Salem | Wisconsin | 54669 | United States |
| Hospital Italiano de Buenos Aires | Buenos Aires | C1199 | Argentina |
| IADT Instituto Argentino de Diagnostico y Tratamiento | CABA | C1122 | Argentina |
| Centro Medico Austral | Capital Federal | C1017 | Argentina |
| Hospital Italiano de La Plata | La Plata | B1900AXI | Argentina |
| Hospital Privado de la Comunidad | Mar del Plata | B7602 | Argentina |
| CTO Centro De Tratamento Oncologico LTDA | Belém | 66.073-005 | Brazil |
| Santa Casa de Misericordia de Belo Horizonte | Belo Horizonte | 30150-221 | Brazil |
| Liga Paranaense de Combate ao Cancer | Curitiba | 81520-060 | Brazil |
| Fundacao Doutor Amaral Carvalho | Jaú | 17.210-080 | Brazil |
| Hospital Nossa Senhora da Conceicao S A | Porto Alegre | 91350 200 | Brazil |
| Nucleo de Oncologia da Bahia Oncoclinicas | Salvador | 40170 070 | Brazil |
| Hospital Ana Nery Santa Cruz do Sul | Santa Cruz do Sul | 96835-100 | Brazil |
| Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo | São Paulo | 01246 000 | Brazil |
| Fundacao Antonio Prudente A C Camargo Cancer Center | São Paulo | 01509 900 | Brazil |
| Servicos de Tratamento ao Cancer de Taubate LTDA - Instituto do Cancer Brasil Unidade Taubate | Taubaté | 12030-200 | Brazil |
| Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia | Vitória | 29043-260 | Brazil |
| Changzhou No 2 Peoples Hospital | Changzhou | 213004 | China |
| West China Hospital | Chengdoucun | 610041 | China |
| Sichuan Cancer Hospital | Chengdu | 610041 | China |
| The First Affiliated Hospital Sun Yat sen University | Guangzhou | 510080 | China |
| The First Affiliated Hospital Zhejiang University School of Medicine | Hangzhou | 310003 | China |
| Harbin medical university cancer hospital | Harbin | 150040 | China |
| Huizhou Municipal Central Hospital | Huizhou | 516001 | China |
| Zhongda Hospital Southeast University | Nanjing | 210000 | China |
| Fudan University Shanghai Cancer Center | Shanghai | 200032 | China |
| The First Affiliated Hospital of Xian Jiaotong University | Xi'an | 710061 | China |
| Henan Cancer Hospital | Zhengzhou | 450008 | China |
| Hopital Nord | Marseille | 13915 | France |
| Hopital PASTEUR | Nice | 06001 | France |
| Institut Curie | Paris | 75005 | France |
| Universitaetsklinikum der RWTH Aachen | Aachen | 52074 | Germany |
| Kliniken Essen-Mitte | Essen | 45136 | Germany |
| Universitaetsklinikum Giessen und Marburg GmbH | Giessen | 35392 | Germany |
| Thoraxklinik am Universitatsklinikum Heidelberg | Heidelberg | 69126 | Germany |
| Klinikum Kassel GmbH | Kassel | 34125 | Germany |
| Universitaetsklinikum Schleswig Holstein Campus Kiel | Kiel | 24105 | Germany |
| Hospital Pulau Pinang | George Town | 10450 | Malaysia |
| University Malaya Medical Centre | Kuala Lumpur | 59100 | Malaysia |
| Hospital Tengku Ampuan Afzan | Kuantan | 25100 | Malaysia |
| Hospital Umum Sarawak | Kuching | 93586 | Malaysia |
| Chungbuk National University Hospital | Cheongju-si | 28644 | South Korea |
| Gachon University Gil Medical Center | Incheon | 21565 | South Korea |
| Severance Hospital Yonsei University Health System | Seoul | 03722 | South Korea |
| Hosp Univ A Coruna | A Coruña | 15006 | Spain |
| Hosp. Gral. Univ. de Alicante | Alicante | 03010 | Spain |
| Hosp. Univ. Quiron Dexeus | Barcelona | 08028 | Spain |
| Hosp Univ Vall D Hebron | Barcelona | 08035 | Spain |
| Hosp. Univ. de Jaen | Jaén | 23007 | Spain |
| Hosp. Univ. Lucus Augusti | Lugo | 27003 | Spain |
| Hosp. Gral. Univ. Gregorio Maranon | Madrid | 28007 | Spain |
| Hosp Regional Univ de Malaga | Málaga | 29010 | Spain |
| Hosp. Ntra. Sra. de Valme | Seville | 41014 | Spain |
| National Taiwan University Hospital Hsin Chu Branch | Hsinchu | 30059 | Taiwan |
| Chang Gung Memorial Hospital | Kaohsiung City | 833 | Taiwan |
| Taichung Veterans General Hospital | Taichung | 40705 | Taiwan |
| National Taiwan University Hospital | Taipei | 100 | Taiwan |
| Linkou Chang Gung Memorial Hospital | Taoyuan City | 333 | Taiwan |
| Adana City Hospital | Adana | 1060 | Turkey (Türkiye) |
| Gulhane Training and Research Hospital | Ankara | 06010 | Turkey (Türkiye) |
| Gazi University Hospital | Ankara | 06560 | Turkey (Türkiye) |
| Ankara Bilkent City Hospital | Ankara | 6800 | Turkey (Türkiye) |
| Bakirkoy Training and Research Hospital | Istanbul | 34147 | Turkey (Türkiye) |
| I A U VM Medical Park Florya Hastanesi | Istanbul | 34295 | Turkey (Türkiye) |
| Ege University Medical Faculty | Izmir | 35100 | Turkey (Türkiye) |
| Ondokuz Mayis University | Samsun | 55420 | Turkey (Türkiye) |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000718215 | amivantamab |
| C000707992 | lazertinib |
| D004318 | Doxycycline |
| D008911 | Minocycline |
| D002981 | Clindamycin |
| D002710 | Chlorhexidine |
| C540383 | ruxolitinib |
| D016559 | Tacrolimus |
| C030691 | gluconic acid |
| D011433 | Propranolol |
| D013999 | Timolol |
| D002990 | Clobetasol |
| ID | Term |
|---|---|
| D013754 | Tetracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
| D008034 | Lincomycin |
| D055231 | Lincosamides |
| D011759 | Pyrrolidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D018942 | Macrolides |
| D007783 | Lactones |
| D050198 | Phenoxypropanolamines |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D020005 | Propanols |
| D000588 | Amines |
| D009281 | Naphthalenes |
| D013830 | Thiadiazoles |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D001393 | Azoles |
| D009025 | Morpholines |
| D010078 | Oxazines |
| D001623 | Betamethasone |
| D013259 | Steroids, Fluorinated |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided